ichorbio
ichorbio is a manufacturer of bulk in vivo antibodies and research biosimilars based in Oxford, United Kingdom.
At ichorbio, their vision is to develop the highest quality reagents to advance scientific research and progress. They believe that the excellence of our products directly impacts the meaningfulness of research outcomes.
As a boutique reagent manufacturer, their target customers are scientists seeking reliable antibodies and other research tools. They aim to provide these products at fair prices - keeping our focus on customers, not shareholders.
Thier best selling in vivo products include RMP1-14, 10F.9G2 and 2.43. Their best selling research biosimilars include mosunetuzumab, odronextamab and aflibercept. Their best selling isotype controls include Rat IgG2a isotype control, Rat IgG2b isotype control, Human IgG1 isotype control and Human IgG4 S228P isotype control.
IDEA Regulatory
IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.
Intract Pharma
Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.
Isogenica
Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.
